The immunological footprint of CMV in HIV-1 patients stable on long-term ART

Jacquita Affandi, Jacinta Montgomery, Samantha Brunt, D. Nolan, P. Price

    Research output: Contribution to journalArticlepeer-review

    15 Citations (Scopus)

    Abstract

    © 2015 Affandi et al. Background: Most HIV-infected persons are cytomegalovirus (CMV) seropositive and retain latent virus that can be reactivated by immune activation. Their T cell populations express markers reflecting a late stage of differentiation, but the contributions of HIV and CMV to this profile are unclear. We investigated the immunological "footprint" of CMV in HIV patients who had a history of extreme immunodeficiency but were now stable on antiretroviral therapy (ART). Results: Twenty CMV seropositive HIV patients >50years old with nadir CD4 T-cell counts 12years on ART. 16 CMV seropositive and 9 CMV seronegative healthy controls were included. CMV antibody titres were higher in HIV patients than controls (P <0.001-0.003). Levels of soluble B-cell activating factor (sBAFF) were elevated in patients (P = 0.002) and correlated with levels of CMV antibodies (P = 0.03-0.002), with no clear relationship in controls. CD8 T-cell IFNγ responses to the IE1 peptide (VLE) remained elevated in HIV patients (P = 0.005). The CD57+CD45RA+CD27- phenotype of CD8 T-cells correlated with age (r = 0.60, P = 0.006), antibodies against CMV IE1 protein (r = 0.44, P = 0.06) and CD4 T-cell IFNγ response to CMV lysate (r = 0.45, P = 0.05). Conclusions: Humoral and T-cell responses to CMV remained elevated in HIV patients after >12years on ART. Age and presence of CMV disease influenced CD8 T-cell phenotypes. Elevated levels of sBAFF may be a consequence of HIV disease and contribute to high titres of CMV antibody.
    Original languageEnglish
    Pages (from-to)Article 14
    JournalImmunity and Ageing
    Volume12
    Issue number1
    DOIs
    Publication statusPublished - 2015

    Fingerprint

    Dive into the research topics of 'The immunological footprint of CMV in HIV-1 patients stable on long-term ART'. Together they form a unique fingerprint.

    Cite this